Severe cutaneous interface drug eruption associated with bendamustine.
Bendamustine is an anti-neoplastic agent approved by the FDA in 2008 for use as monotherapy or in combination with other agents to treat chronic lymphocytic leukemia (CLL) and progressed indolent B-cell non-Hodgkin lymphoma (NHL). In clinical trials and post-marketing safety reports administration of bendamustine with drugs that have known adverse reactions (i.e., allopurinol, rituximab) has been associated with rash, toxic skin reactions, and bullous exanthems. Here, we describe a patient with NHL who developed a severe cutaneous reaction associated with the administration of bendamustine. The severity of this drug eruption identifies an important adverse reaction with this drug and a potential cause for patient morbidity.
Alamdari
Habibollah S
HS
Division of Dermatology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Pinter-Brown
Lauren
L
Cassarino
David S
DS
Chiu
Melvin W
MW
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D003520:Cyclophosphamide / Q000627:therapeutic use; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D014750:Vincristine; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; D011241:Prednisone